Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013
Financial Results

BERKELEY HEIGHTS, N.J., March 13, 2014 (GLOBE NEWSWIRE) -- Cyclacel
Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the
"Company"), a biopharmaceutical company developing oral therapies that target
the various phases of cell cycle control for the treatment of cancer and other
serious disorders, will announce fourth quarter and full year 2013 financial
results on Tuesday, March 25, 2014. The Company will host a conference call
and live webcast at 4:30 pm Eastern time on the same day.

Conference call information:

US/Canada call: (877) 493-9121 / international call: (973) 582-2750

US/Canada archive: (800) 585-8367 / international archive: (404) 537-3406

Code for live and archived conference call is 9003037

For the live and archived webcast, please visit the Corporate Presentations
page on the Cyclacel website at www.cyclacel.com. The webcast will be archived
for 90 days and the audio replay for 7 days.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target
the various phases of cell cycle control for the treatment of cancer and other
serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is
the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the
FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly,
and other studies for myelodysplastic syndromes (MDS), chronic lymphocytic
leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic
cancer and in particular those carrying gBRCA mutations. Cyclacel's strategy
is to build a diversified biopharmaceutical business focused in hematology and
oncology based on a development pipeline of novel drug candidates. Please
visit www.cyclacel.com for additional information.

© Copyright 2014 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The
Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. 

CONTACT: Contacts for Cyclacel Pharmaceuticals, Inc.
        
         Company: Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com
         Investor Relations: Russo Partners LLC, Robert Flamm,
         (212) 845-4226, robert.flamm@russopartnersllc.com

Cyclacel Pharmaceuticals logo
 
Press spacebar to pause and continue. Press esc to stop.